Silence Therapeutics (NASDAQ:SLN – Get Free Report) and MediWound (NASDAQ:MDWD – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.
Analyst Ratings
This is a summary of current recommendations and price targets for Silence Therapeutics and MediWound, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silence Therapeutics | 1 | 0 | 3 | 1 | 2.80 |
| MediWound | 1 | 1 | 2 | 0 | 2.25 |
Silence Therapeutics currently has a consensus target price of $55.00, suggesting a potential upside of 815.14%. MediWound has a consensus target price of $34.00, suggesting a potential upside of 137.76%. Given Silence Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Silence Therapeutics is more favorable than MediWound.
Risk & Volatility
Insider and Institutional Ownership
98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Silence Therapeutics and MediWound”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silence Therapeutics | $560,000.00 | 506.99 | -$88.61 million | ($1.59) | -3.78 |
| MediWound | $16.96 million | 10.83 | -$23.88 million | ($2.26) | -6.33 |
MediWound has higher revenue and earnings than Silence Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Silence Therapeutics and MediWound’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Silence Therapeutics | -8,943.86% | -105.34% | -52.79% |
| MediWound | -180.30% | -67.22% | -31.87% |
Summary
Silence Therapeutics beats MediWound on 9 of the 15 factors compared between the two stocks.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
